All News

Chiadi Ndumele, MD, PhD, MHS, of Johns Hopkins University, details features of the new 4-stage construct that guides CKM diagnosis and promotes early disease intervention.

Polycystic ovary syndrome and dysmenorrhea were both identified as reproductive disorders that could help stratify CVD risk in women.

AHA 2023: An intensive 3-year treatment targeting SPB <120 mm Hg resulted in 39% lower CV mortality than standard treatment in patients with HTN at high risk of CVD.

Your daily dose of the clinical news you may have missed.

According to the US CDC, the most important modifiable risk factor for antibiotic resistance is (fill in this blank). Find out here and fill in 5 more blanks.

Ndumele chairs the American Heart Association committee that characterized the syndrome and wrote the statement of evidence for its assessment and management.

TLM 2023: Speech analyzed from a smartphone app recording identified MHE and predicted OHE with results comparable to those from validated assessments.

November is Alzheimer Awareness Month and a good time to look at common myths held by clinicians and patients alike - and the facts to refute them.

Which hypertension treatment options should be used as first-line therapy in patients with obesity? A clinician's answer and explanation, here.

Your daily dose of the clinical news you may have missed.

AHA 2023: Semaglutide 2.4 mg reduced the risk of serious cardiovascular events by 20% in patients with obesity and overweight with established CVD but without diabetes, according to full SELECT trialresults.

More education that is clear and from reliable sources is needed for patients with a NASH diagnosis and their caregivers throughout the duration of the disease.

One in 5 patients identified as at risk for advanced chronic liver disease had advanced fibrosis and PCP was prompted to refer to hepatology.

TLM 2023: Primary care clinicians exposed to a FIB4-based risk stratification algorithm reported applying it routinely for patients with elevated LFTs after the introduction.

TLM 2023: Over 15 years, decompensated cirrhosis and OHE notably rose among Medicare beneficiaries with cirrhosis, exceeding 40% and 20% in 2020.

TLM 2023: The simple noninvasive tool may be an alternative to FIB-4, researchers said, and the new data may have implications for NAFLD surveillance.

The predictive algorithm uses FibroScan-captured CAP and LSM data plus 5 clinical variables to identify advanced fibrosis in persons with MASLD.

TLM 2023: The burden of CAD is similar between persons with hepatic steatosis at low and high ASCVD risk, but rate of MACE is higher in the low-risk population.